Get the Stockscreener App
0.2485
2.05%
0.005
Pre-market:
.25
0.0015
+0.60%
Cellectar Biosciences Inc stock is traded at $0.2485, with a volume of 1.39M.
It is up +2.05% in the last 24 hours and up +5.74% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
See More
Previous Close:
$0.2435
Open:
$0.2463
24h Volume:
1.39M
Relative Volume:
0.62
Market Cap:
$10.26M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.0765
EPS:
-3.25
Net Cash Flow:
$-30.91M
1W Performance:
-9.64%
1M Performance:
+5.74%
6M Performance:
-90.14%
1Y Performance:
-92.86%
1-Day Range:
$0.234
$0.2499
1-Week Range:
$0.2298
$0.2666
52-Week Range:
$0.224
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
0.2485 | 10.26M | 0 | -37.75M | -30.91M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire
Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar stock plunges 50% post-market on restructuring news - MSN
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold
Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register
Neuroblastoma Therapeutic Market: Analyzing the Impact of High - openPR
Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN
Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World
Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World
Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha
CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan
Cellectar refocuses on solid tumor radiotherapies - Investing.com
Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire
Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan
Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart
Waldenstrom Macroglobulinemia Market Growth to Accelerate - openPR
Cellectar Biosci stock hits 52-week low at $1.38 By Investing.com - Investing.com Canada
Cellectar Biosci stock hits 52-week low at $1.38 - Investing.com
Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target - Quantisnow
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? - AOL
Cellectar Biosciences (STU:NV4) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Volatility : 73.35% (As of Nov. 29, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Total Stockholders Equity : €13.66 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) PE Ratio : At Loss (As of Nov. 28, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Other Long Term Assets : €0.03 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Current Accrued Expense : €7.48 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Quick Ratio : 1.77 (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com
CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com
12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):